Cancer is one of the most devastating diseases that is extremely prevalent to modern society and medicine and still poses a big challenge in defeating it. While treatments like surgery, chemotherapy, immunotherapy, and radiation therapy do exist, they can be very harmful to the body and can’t eradicate the disease very proficiently. In recent years, scientists have developed a new type of therapy that has captured the attention of the scientific community as well as the public, which is CAR-T cell therapy. CAR-T cell therapy is an immunotherapy that uses the body’s own immune response to hunt down and destroy cancerous cells.1,2 With dramatic remission rates in hematological cancers, researchers in the field have called it a revolutionary breakthrough. Although there are big improvements from the prior treatments, CAR-T cell therapy still has work to be done with solid tumors in order to become the golden ticket to treating cancer.
CAR-T cell therapy works due to a biological process known as adoptive cell transfer where a patient’s own T-cells, an immune cell responsible for attacking pathogens and diseases, are extracted from the body, engineered in a laboratory to carry specific proteins, and then reintroduced into the patient’s body.3 The engineered proteins act like a targeting system and allow the T cells to recognize and bind to specific proteins on the surface of the cancer cells. Once the T cells recognize the specific proteins, the T cells release cytotoxins and other chemical signals to recruit immune cells in order to destroy the tumor. The reason this therapy is so amazing is the fact that it is specific rather than just flooding the body with drugs that could harm health tissue.
The Disappearing Act: How Cancer Evades Treatment Through Antigen Escape
The ability for cancer to evolve is one of the most frustrating reasons that treatments still fail. While CAR-T cells are engineered to recognize specific antigens, the tumors can alter its genetic makeup and get rid of that signal that allows engineered T cells to identify them.4,5 This is known as antigen escape and is a primary reason for failure of CAR-T cell therapy in solid tumors. A great example of this is CD19, which is a protein found on an immune cell called a B cell, where initial remission rates in hematological cancer patients were extremely high. In this example, about thirty to seventy percent of patients relapsed 6 and it was found that when the cancer did return, it was CD19 negative meaning that the cancer mutated to get past the therapy that was meant to target it.
To respond to this issue, researchers are developing dual-CAR and tandem-CAR systems that help target two or more antigens at once simultaneously.3 The logic behind this change in treatment plan is that it is much harder for a tumor to mutate past the target antigen if there is more than one antigen to mutate past. The multi-antigen approach also helps to reduce the risk of accidentally triggering healthy tissue attacks since the combination of antigens is more unique to cancerous cells. The challenge from this emerges from the fact that it is hard to identify multiple reliable targets within a specific tumor as well as the lack of understanding of safety implications of a more complex targeting system.
Immune System on Overdrive: Understanding Cytokine Release Syndrome
When engineered CAR-T cells meet a tumor, it isn’t a quiet eviction but instead an all out cellular war. The resulting fire and smoke from this cellular war is what medical practitioners call Cytokine Release Syndrome (CRS). When CAR-T cells activate within the body they trigger a huge inflammatory response which floods the body with chemical signals that can overwhelm the system.3,7 Forty to ninety percent of patients that received CAR-T infusions had symptoms of CRS which makes it the most common, serious side effect of the treatment.
The symptoms start to develop with the patient first having a fever and then can escalate to a racing heart, low blood pressure, headaches, difficulty breathing, organ dysfunction, and death in severe cases.3,4,5,6,7,8,9 What makes CRS stand out from other side effects is that most patients that are receiving the treatment are already susceptible to health issues due to prior health complications or previous treatments. These symptoms usually present themselves within a few hours to days but peak at around the first or second week after infusion, which coincidentally is when the therapy is doing the most work.
Current management of this treatment surrounds using a treatment that blocks IL-6, a primary signaling molecule driving the inflammatory pathway.4,5,6,7,9 Tocilizumab, an FDA approved IL-6 receptor blocker, has become a common approach for intervening against CRS and can be combined with corticosteroids to effectively manage cases. This isn’t a definitive answer as it is reactive and not preventive which is why it is still a major barrier against successful CAR-T therapy usage.
The Tumor’s Fortress: The Challenge of the Immunosuppressive Tumor Microenvironment
Even when CAR-T cells reach a tumor successfully and recognize their target, the tumor fights back by transforming the environment around it. Solid tumors are exceptionally good at this as the complex ecosystem known as the tumor microenvironment surrounds the tissue and is known to protect the cancer. A group of immune cells recruited by the tumor all work together to worsen treatment efficacy while also creating a tumor-friendly environment inside of the body.3,4,5,6,10
Another issue brought about by the tumor microenvironment is the addition of a protein, called checkpoint proteins, which stops overactive immune cells in killing the tumor. By exploiting the ability to turn off these proteins, cancer can render the CAR-T cells useless. One study showed that patients relapsed after CAR-T cell therapy and a test showed a high amount of one checkpoint protein, PD-L1, on the cancer’s surface.10 It suggests that this specific protein plays an important role in the recovery of cancer after CAR-T cell therapy and needs to be targeted in future studies.
The most promising response to this has been to combine CAR-T cell therapy with another immunotherapy. A study showed that combining the two therapies showed a seventy two percent response rate in patients.6 Another promising study from the Children's Hospital of Pennsylvania found that the combination of an immunotherapy and CAR-T cell therapy improved the persistence of the treatment and could be used to improve the treatment plans of patients.4 While this approach shows promising effects, researchers are worried about the sufficiency of the treatment as the tumor microenvironment presents many suppressing mechanisms for any single combination of therapies to overcome.
Burned Out: How T Cells Lose the Fight Against Cancer
The biggest limitation of CAR-T cell therapy lies with T cell exhaustion which is a state where T cells that have been fighting the cancer lose the ability to function.3 To effectively treat cancer, treatment requires CAR-T cells to remain active over a long period of time while also still hunting down cancerous cells. The prolonged exposure to tumor antigens pushes T cells into a state of exhaustion where they produce less positive chemical signals, stop reproducing, and gradually stop killing target cells.11,12
The statistics show that T cell exhaustion is related to relapse rate in approximately seventy five percent of patients treated with CD19 or CD22 CAR-T cells for hematological cancers. When T cells get exhausted, they start to help tumors suppress immunity causing compounding failures. Right when the T cells are needed the most, they begin to fail due to exhaustion and cause the failure of the treatment.
To address T cell exhaustion researchers have focused on improving chemical signaling as well as adapting CAR protein expression over the surface of T cells.11,12 Both strategies show promise but researchers also acknowledge that the biology behind the exhaustion is not fully understood which means that moving forward without the understanding can carry real risks in a clinical setting
What This Means for the Future of Cancer Treatment
CAR-T cell therapy is not a failed method but instead is an extraordinary scientific achievement that has saved lives that previous treatments could not. For patients with certain blood-based cancers, it has produced outcomes that were unthinkable just ten years ago. The gap between those early successes and a broad applicable treatment is still there and understanding the four key barriers are essential in bridging this gap.
What makes this moment in research so significant is that these are not problems on their own that require their own solutions, but instead a deeply interconnected problem. The exhausted T cells express the same checkpoints that the tumor exploits, cytokine storms share biological pathways with the suppressive signals in the tumor microenvironment, and antigen escape is more likely to succeed when the immune response is already weakened by exhaustion or suppression. Progress on one front will help achieve progress on the others as well which is monumental.
The era of treating cancer by broadly poisoning the body is coming to an end and is giving way to a new treatment that is more specific, smart, and humane. CAR-T cell therapy represents a fundamental shift in oncology by moving us away from attacking the disease from the outside and towards mobilizing the body’s own defenses from within. While obstacles remain, they’re not roadblocks but instead final milestones. Overcoming these four barriers means a future where a cancer diagnosis no longer demands a brutal physical battle and instead prompts a quick and quiet takedown of the cancer by the patient’s own immune system. By mastering these challenges, we can stop fighting the disease and finally enter an era where cancer is decisively outsmarted.
References
No comments:
Post a Comment